Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The adjuvanticity of gamma inulin.

Identifieur interne : 002E49 ( Main/Exploration ); précédent : 002E48; suivant : 002E50

The adjuvanticity of gamma inulin.

Auteurs : P D Cooper ; E J Steele

Source :

RBID : pubmed:3265692

Descripteurs français

English descriptors

Abstract

Gamma-inulin (g-IN) is a polymorph identified as the active component of inulin preparations that specifically activates the alternative pathway of complement (APC). The APC is central to many leucocyte functions, including B cell activation. We show here that g-IN, when formulated as a pure, endotoxin-free, fine suspension insoluble at 37 degrees C and given at 50-100 micrograms per mouse, is a potent adjuvant for both humoral and cell-mediated responses to a variety of antigens. g-IN increased secondary IgG responses five- to 28-fold (P less than 0.001), using as antigen phosphorylcholine coupled to keyhole limpet haemocyanin; subclasses IgG 2a, 2b, and 3 were boosted several hundred-fold, IgG 1 10-fold. IgM and IgA were increased four- to six-fold. Delayed hypersensitivity, by footpad swelling after secondary challenge with sheep red blood cells (SRBC), was increased more than two-fold (P less than 0.001) if g-IN was included with the primary SRBC, equivalent to increasing primary doses 10-fold. g-IN was equally active if given 5 days before the primary SRBC. Thus it is an immune stimulant rather than a depot or vehicle for antigen. Mice primed subcutaneously with 30-300 HA units of H2N2 influenza virus (strain A/JAP) and challenged intranasally with a lethal dose of H1N1 virus (strain A/WSN) all died, but if g-IN was given with the primary antigen 50% of the mice survived (P less than 0.001), a deduced but not proven boost to cytotoxic T cell-mediated immunity. Unpublished work has shown that g-IN has no adverse effects at adjuvant-active doses.(ABSTRACT TRUNCATED AT 250 WORDS)

DOI: 10.1038/icb.1988.45
PubMed: 3265692


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The adjuvanticity of gamma inulin.</title>
<author>
<name sortKey="Cooper, P D" sort="Cooper, P D" uniqKey="Cooper P" first="P D" last="Cooper">P D Cooper</name>
<affiliation>
<nlm:affiliation>Division of Virology and Cellular Pathology, John Curtin School of Medical Research, Australian National University, Canberra, ACT.</nlm:affiliation>
<wicri:noCountry code="subField">ACT</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Steele, E J" sort="Steele, E J" uniqKey="Steele E" first="E J" last="Steele">E J Steele</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="????">
<PubDate>
<MedlineDate>1988 Oct-Dec</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:3265692</idno>
<idno type="pmid">3265692</idno>
<idno type="doi">10.1038/icb.1988.45</idno>
<idno type="wicri:Area/PubMed/Corpus">000469</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000469</idno>
<idno type="wicri:Area/PubMed/Curation">000469</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000469</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000633</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000633</idno>
<idno type="wicri:Area/Ncbi/Merge">001060</idno>
<idno type="wicri:Area/Ncbi/Curation">001060</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001060</idno>
<idno type="wicri:doubleKey">0818-9641::Cooper P:the:adjuvanticity:of</idno>
<idno type="wicri:Area/Main/Merge">003024</idno>
<idno type="wicri:Area/Main/Curation">002E49</idno>
<idno type="wicri:Area/Main/Exploration">002E49</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The adjuvanticity of gamma inulin.</title>
<author>
<name sortKey="Cooper, P D" sort="Cooper, P D" uniqKey="Cooper P" first="P D" last="Cooper">P D Cooper</name>
<affiliation>
<nlm:affiliation>Division of Virology and Cellular Pathology, John Curtin School of Medical Research, Australian National University, Canberra, ACT.</nlm:affiliation>
<wicri:noCountry code="subField">ACT</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Steele, E J" sort="Steele, E J" uniqKey="Steele E" first="E J" last="Steele">E J Steele</name>
</author>
</analytic>
<series>
<title level="j">Immunology and cell biology</title>
<idno type="ISSN">0818-9641</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adjuvants, Immunologic</term>
<term>Animals</term>
<term>Complement Pathway, Alternative</term>
<term>Female</term>
<term>Hemocyanins (immunology)</term>
<term>Hypersensitivity, Delayed</term>
<term>Immunoglobulins (biosynthesis)</term>
<term>Inulin (pharmacology)</term>
<term>Mice</term>
<term>Mice, Inbred Strains</term>
<term>Orthomyxoviridae (immunology)</term>
<term>T-Lymphocytes, Cytotoxic (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Hypersensibilité retardée</term>
<term>Immunoglobulines (biosynthèse)</term>
<term>Inuline (pharmacologie)</term>
<term>Lignées consanguines de souris</term>
<term>Lymphocytes T cytotoxiques (immunologie)</term>
<term>Orthomyxoviridae (immunologie)</term>
<term>Souris</term>
<term>Voie alterne d'activation du complément</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Immunoglobulins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Hemocyanins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Inulin</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>Immunoglobulines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Lymphocytes T cytotoxiques</term>
<term>Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Orthomyxoviridae</term>
<term>T-Lymphocytes, Cytotoxic</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Inuline</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Complement Pathway, Alternative</term>
<term>Female</term>
<term>Hypersensitivity, Delayed</term>
<term>Mice</term>
<term>Mice, Inbred Strains</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Hypersensibilité retardée</term>
<term>Lignées consanguines de souris</term>
<term>Souris</term>
<term>Voie alterne d'activation du complément</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Gamma-inulin (g-IN) is a polymorph identified as the active component of inulin preparations that specifically activates the alternative pathway of complement (APC). The APC is central to many leucocyte functions, including B cell activation. We show here that g-IN, when formulated as a pure, endotoxin-free, fine suspension insoluble at 37 degrees C and given at 50-100 micrograms per mouse, is a potent adjuvant for both humoral and cell-mediated responses to a variety of antigens. g-IN increased secondary IgG responses five- to 28-fold (P less than 0.001), using as antigen phosphorylcholine coupled to keyhole limpet haemocyanin; subclasses IgG 2a, 2b, and 3 were boosted several hundred-fold, IgG 1 10-fold. IgM and IgA were increased four- to six-fold. Delayed hypersensitivity, by footpad swelling after secondary challenge with sheep red blood cells (SRBC), was increased more than two-fold (P less than 0.001) if g-IN was included with the primary SRBC, equivalent to increasing primary doses 10-fold. g-IN was equally active if given 5 days before the primary SRBC. Thus it is an immune stimulant rather than a depot or vehicle for antigen. Mice primed subcutaneously with 30-300 HA units of H2N2 influenza virus (strain A/JAP) and challenged intranasally with a lethal dose of H1N1 virus (strain A/WSN) all died, but if g-IN was given with the primary antigen 50% of the mice survived (P less than 0.001), a deduced but not proven boost to cytotoxic T cell-mediated immunity. Unpublished work has shown that g-IN has no adverse effects at adjuvant-active doses.(ABSTRACT TRUNCATED AT 250 WORDS)</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Cooper, P D" sort="Cooper, P D" uniqKey="Cooper P" first="P D" last="Cooper">P D Cooper</name>
<name sortKey="Steele, E J" sort="Steele, E J" uniqKey="Steele E" first="E J" last="Steele">E J Steele</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E49 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E49 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:3265692
   |texte=   The adjuvanticity of gamma inulin.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:3265692" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021